Drug class in one race
IL-23 p19 drugs for Crohn's Disease
7 tracked IL-23 p19 drugs in the Crohn's Disease race. The class explanation lives on the IL-23 p19 page; the full indication pipeline across every mechanism is on the Crohn's Disease page.
5 approved / phase 41 Phase 31 Phase 2
Head-to-head evidence: guselkumab vs JNJ-78934804 · JNJ-78934804 vs mirikizumab · JNJ-78934804 vs risankizumab · guselkumab vs MT-201 · mirikizumab vs MT-201 · MT-201 vs risankizumab